PMID

Data

Article Title

Organization

Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.

Glaxosmithkline

Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.

Sanofi

Colloidal aggregation causes inhibition of G protein-coupled receptors.

University Of North Carolina At Chapel Hill

Identification of a sulfonamide series of CCR2 antagonists.

Glaxosmithkline

Recent developments and biological activities of thiazolidinone derivatives: a review.

Dr. Hari Singh Gour University

In vivo activity of an azole series of CCR2 antagonists.

Glaxosmithkline

Chemokine receptor antagonists.

National Heart And Lung Institute

Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation.

Glaxosmithkline

CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.

Glaxosmithkline

Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.

Telik

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

Genzyme

Spiropiperidine CCR5 antagonists.

Roche Palo Alto

Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice.

Chinese Academy Of Medical Sciences And Peking Union Medical College

Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.

Astellas Pharma

Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.

Roche Palo Alto

Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.

Astellas Pharma

Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines.

Astellas Pharma

Small molecule antagonists of the CC chemokine receptor 4 (CCR4).

Millennium Pharmaceuticals

Core exploration in optimization of chemokine receptor CCR4 antagonists.

Bristol-Myers Squibb Pharmaceutical Research Institute

Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.

Merck Research Laboratories

Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.

Takeda Pharmaceutical

Optimization of 2-aminothiazole derivatives as CCR4 antagonists.

Amgen

Optimization of CCR4 antagonists: side-chain exploration.

Bristol-Myers Squibb Pharmaceutical Research Institute

Identification of chemokine receptor CCR4 antagonist.

Bristol-Myers Squibb Pharmaceutical Research Institute

Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.

Array Biopharma

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

Merck Research Laboratories

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

Merck Research Laboratories

Design, synthesis, and discovery of a novel CCR1 antagonist.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.

Merck Research Laboratories

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.

Takeda Chemical Industries

2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis.

Glaxosmithkline Medicines Research Centre

Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.

Glaxosmithkline

Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.

Astrazeneca

Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.

Glaxosmithkline

Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.

Gsk Pharmaceuticals R & D

Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.

Osaka University Of Pharmaceutical Sciences